RxDoctor Payments Data

Jason Reingold, MD

Cardiovascular Disease · Alpharetta, GANPI 1639374283

Payments from drug & device makers

$35,528in general payments, 2019–2025

Across 72 payments — averaging $493.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$34K
  • Pfizer$233
  • Inari Medical, Inc.$189
  • Amgen$124
  • Heartflow, Inc.$99
  • Boston Scientific$94
  • plus $515 from 15 others

What the payments were for

  • Speaking & faculty fees$29,57583%
  • Travel & lodging$3,87111%
  • Food & beverage$2,0816%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,528 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$82,518
Medicare patients
139
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$15,636
EntrestoSacubitril/Valsartan15$13,098
XareltoRivaroxaban16$11,195
Atorvastatin Calcium32$373
Amlodipine Besylate55$330
Metoprolol Succinate29$291
Nitroglycerin32$283
Nifedipine ErNifedipine13$272
Ezetimibe26$268
Hydralazine Hcl17$252
Rosuvastatin Calcium45$234
Losartan Potassium22$183
Lisinopril20$55
Furosemide17$49
Metoprolol Tartrate15$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$15,63615 claims
NovartisEntresto$79$13,09815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →